New Jersey-based SK Life Science announced refunds for 340B covered entities that purchased certain formulations of anti-seizure drug XCOPRI.

SK Life Science Announces 340B Refunds for Epilepsy Treatment

April 15, 2025 Bella Czajkowski, National Correspondent Views

SK Life Science recently issued a refund notice for an epilepsy drug following a 340B price ceiling recalculation. The New [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!